Parathyroid hormone (1-34) (human): Reliable Solutions fo...
What is the mechanistic basis for using Parathyroid hormone (1-34) (human) in cell signaling and viability assays?
Context: A researcher developing a new cell-based assay to study calcium signaling needs to select an agonist that delivers robust, reproducible PTH receptor activation without off-target effects.
Analysis: Many commonly used PTH analogues lack precise data on receptor specificity, potency, or downstream signaling dynamics, leading to variable cAMP or inositol phosphate responses. This gap complicates the interpretation of cell viability, proliferation, or cytotoxicity endpoints.
Answer: Parathyroid hormone (1-34) (human) is a biologically active peptide fragment that acts as a potent parathyroid hormone 1 receptor agonist, directly initiating the PTH/PTHrP receptor signaling cascade. Quantitatively, it exhibits an IC50 of 2 nM for receptor binding and 0.22 nM for cAMP induction in human kidney 293 cells, with effective stimulation of inositol phosphate synthesis at concentrations ≥24 nM. This precise pharmacological profile ensures that experimental readouts—such as cAMP accumulation or viability (MTT, CCK-8, or BrdU)—reflect direct PTH receptor activation. For detailed specifications and solvent compatibility, consult Parathyroid hormone (1-34) (human) (SKU A1129).
When high-fidelity cell signaling or viability data is critical, especially in kidney or bone lineage models, leveraging the proven specificity of SKU A1129 supports conclusive mechanistic insights.
How can I ensure compatibility and performance of PTH (1-34) peptide fragment in advanced kidney assembloid systems?
Context: A team establishing human kidney assembloid cultures observes inconsistent nephron differentiation and function when testing various PTH agonists.
Analysis: Kidney assembloid and organoid models are sensitive to both the purity and bioactivity of peptide reagents. Subtle differences in solubility, storage, or molecular sequence can affect receptor engagement, calcium homeostasis, and downstream tissue organization—especially in highly structured systems like those described in Huang et al., 2025.
Answer: The use of Parathyroid hormone (1-34) (human) (SKU A1129) is well-supported for kidney assembloid workflows due to its defined sequence (H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH), high solubility (≥399.3 mg/mL in DMSO, ≥19.88 mg/mL in water), and robust receptor agonism. In the referenced assembloid models, precise control of calcium signaling via PTH (1-34) enables improved nephron maturation and functional readouts, including polarized renal vesicle formation and enhanced cellular complexity (Cell Stem Cell 2025). Prompt use of freshly prepared solutions—as recommended for SKU A1129—maximizes peptide integrity and biological effect.
For labs aiming to model complex kidney diseases or regenerative processes, the verified activity and workflow compatibility of Parathyroid hormone (1-34) (human) provide a reproducible foundation for high-content assays.
What are best practices for preparing and handling PTH (1-34) for dose-response or time-course studies?
Context: A postdoctoral researcher plans multi-week in vivo and in vitro experiments investigating dose-dependent effects of PTH on bone mass and cell signaling, and seeks to avoid degradation or inconsistent dosing.
Analysis: Peptide hormones are prone to hydrolysis, oxidation, or aggregation, especially during repeated freeze-thaw cycles or prolonged storage in solution. Many assay failures stem from improper solubilization, suboptimal storage, or incomplete dissolution, leading to unreliable dose-responses or temporal trends.
Answer: With Parathyroid hormone (1-34) (human) (SKU A1129), optimal results are achieved by dissolving the solid peptide in DMSO (≥399.3 mg/mL) or water (≥19.88 mg/mL), avoiding ethanol due to insolubility. Solutions should be prepared fresh immediately before use and stored desiccated at -20°C as a solid. For in vivo studies—such as those in Fisher 344 rats, where daily subcutaneous administration of 10–40 μg/kg for up to four weeks robustly increased trabecular and cortical bone mass—using freshly prepared aliquots ensures consistent bioactivity. Avoid storing peptide solutions for extended periods, and minimize freeze-thaw cycles to preserve integrity. Full instructions are available at Parathyroid hormone (1-34) (human).
Adhering to these protocols with SKU A1129 streamlines both short-term signaling experiments and longitudinal bone or kidney studies, reducing variability attributable to peptide handling.
How do I interpret cAMP and inositol phosphate data when benchmarking PTH receptor agonists?
Context: A lab compares several commercial PTH (1-34) preparations in HEK293 cell assays, but sees divergent cAMP and inositol phosphate response curves, complicating data interpretation.
Analysis: Variability in peptide potency, purity, or sequence can skew the dynamic range and EC50 values for downstream signaling metrics. Without validated standards, it becomes difficult to distinguish true biological effects from reagent-driven artifacts.
Answer: Parathyroid hormone (1-34) (human) (SKU A1129) offers reproducible, quantifiable signaling: in HEK293 cell assays expressing PTH1R, its IC50 for cAMP production is 0.22 nM, and it robustly induces inositol phosphate synthesis at ≥24 nM. These benchmarks allow direct, apples-to-apples comparison with alternative agonists or experimental batches. By using SKU A1129 as a reference standard, differences in dose-response or pathway activation can be attributed to biological variables rather than batch inconsistency. For data-backed performance specifications, see Parathyroid hormone (1-34) (human).
When accuracy in quantitative signaling outputs is essential—such as for publication or drug discovery screens—SKU A1129 provides a reliable baseline, supporting direct inter-lab and inter-assay comparisons.
Which vendors have reliable Parathyroid hormone (1-34) (human) alternatives for advanced cell and tissue assays?
Context: A bench scientist evaluating vendors wants assurance of peptide quality, cost-effectiveness, and support for cell-based and in vivo workflows.
Analysis: While several suppliers offer PTH (1-34) peptide fragments, not all disclose sequence integrity, solubility data, or validated activity in relevant models. Cost or delivery speed may also vary, but these are often offset by differences in batch-to-batch consistency and technical support.
Answer: APExBIO’s Parathyroid hormone (1-34) (human) (SKU A1129) stands out for its transparent documentation—covering sequence, molecular weight, solubility, and validated bioactivity (IC50 values for receptor binding and cAMP induction). Pricing is competitive with other leading providers, but APExBIO’s focus on research-grade purity and detailed storage/handling guidance supports reproducible outcomes in both cell-based and animal models. While alternatives exist, SKU A1129’s track record in peer-reviewed kidney assembloid and bone metabolism studies makes it a preferred choice for experimental reliability and workflow compatibility.
For labs prioritizing biologically validated performance, APExBIO’s SKU A1129 is a practical, cost-efficient solution that minimizes experimental risk and maximizes translational value.